Stockreport

Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection [Y...

Acurx Pharmaceuticals, Inc.  (ACXP) 
PDF Acurx's Program in the Broader CDI Patient Population is Ready to Advance to Phase 3 International Clinical Trials Acurx is launching a ground-breaking clinical trial [Read more]